WilmerHale Represents Alcresta Therapeutics in Acquisition by Linden Capital Partners 

WilmerHale Represents Alcresta Therapeutics in Acquisition by Linden Capital Partners 

Client News

Related Solutions

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
Offering a sophisticated, full-service solution to private equity sponsors and entrepreneurs, from initial investment to exit.

On March 12, 2024, Linden Capital Partners, a private equity firm focused exclusively on the healthcare industry, announced the completion of its acquisition of Alcresta Therapeutics, a leader in commercializing novel enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta recently announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration. The next-generation RELiZORB device was developed to address the enteral nutrition needs of a wider population of patients living with rare diseases and is expected to launch in Q2 2024.

The WilmerHale team representing Alcresta was led by Hal Leibowitz, Caroline Dotolo, J.C. Minko, Taylor Mielnicki, Molly Nelson, and Meghan McDuff, with support from Kim Wethly, Scott Kilgore, Justin Ochs, Chalyse Robinson, Julie Hogan Rodgers, Steven Barrett, Kirk Nahra, Doug Burton, Bruce Manheim, Hartmut Schneider, Barry Hurewitz, David Gold, Atul Jain, Alex Dean, Simona Altshuler, and Carla Gilbertson.  

 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel